Clinical Impact of JAK Inhibition in Vitiligo: Efficacy, Repigmentation, and Safety Insights

Welcome back to another Managed Healthcare Executive Population Health Perspectives series. In this episode titled, Clinical Impact of JAK Inhibition in Vitiligo: Efficacy, Repigmentation, and Safety Insights, Dr. Seemal Desai led the conversation about the following questions:

Which inflammatory chemokines associated with melanocyte destruction are reduced with JAK inhibition?

What percentage of patients achieved F-VASI75 at week 24 in the TRuE-V1 and TRuE-V2 trials?

What improvements in repigmentation were observed after 52 weeks of treatment with ruxolitinib cream?

What were the most commonly reported adverse events associated with ruxolitinib cream in clinical trials and how are you monitoring/managing these?

JAK inhibition has been shown to reduce key inflammatory chemokines involved in melanocyte destruction, particularly CXCL9 and CXCL10, which are central to interferon-γ–mediated immune responses in vitiligo. In the TRuE-V1 and TRuE-V2 trials, approximately 30% of patients treated with ruxolitinib cream achieved F-VASI75 at week 24, demonstrating meaningful facial repigmentation compared with vehicle. Continued treatment through 52 weeks led to further improvements, with a greater proportion of patients achieving higher thresholds of repigmentation and more visible, sustained pigment restoration. The most commonly reported adverse events included application-site acne, pruritus, and nasopharyngitis, and in clinical practice these are typically monitored through routine skin assessments and managed with supportive care or treatment adjustments as needed.

In the next episode, Long-Term Repigmentation Outcomes and Real-World Use of Ruxolitinib Cream, Dr. Desai discusses the pooled 104-week analysis of the TRuE-V program, in which sustained and progressive repigmentation was observed, with a substantial proportion of patients achieving F-VASI75 and higher thresholds over time, highlighting the benefit of continued treatment. In clinical practice, ruxolitinib cream is typically used in patients with nonsegmental vitiligo involving the face or limited body surface area, though access can vary due to insurance coverage and prior authorization requirements.